EssilorLuxottica Shares Rise 2.37% After Record Quarterly Results
The stock of the Franco-Italian optical giant ended Thursday's session sharply higher at the Paris Stock Exchange, buoyed by the release of its third-quarter revenue and the announcement of a strategic acquisition in artificial intelligence applied to eye health the day before.
Market Performance and Investor Sentiment
The stock closed at 276.60 euros, up 2.37% from the previous day's 270.20 euros. This increase is part of a favorable three-month trend, with a cumulative gain of 14.2%, although the past week saw a slight decline of 0.75%. Trading remained moderate, with only 0.08% of the capital exchanged, indicating a measured positioning by investors. Over one year, the group's performance reached 27.94%, significantly outperforming the CAC 40's 8.86%, which itself rose by 1.38% during this session. This outperformance of the stock compared to the Parisian index is notably due to a marked defensive positioning, with a beta of -0.07 indicating a very low correlation with market movements. This technical characteristic reflects the group's ability to operate independently of general trends, which can attract investors seeking diversification in a volatile context. The monthly volatility of the stock stands at 5.32%, a contained level that demonstrates relative short-term price stability.
Record Quarterly Revenue and Strategic Acquisitions
The day's increase coincided with the evening release of third-quarter 2025 revenue, which amounted to 6.87 billion euros, up 11.7% at constant exchange rates compared to the same period the previous year. The group described this performance as the best quarterly achievement since its creation in 2018, driven by strong demand for its smart glasses developed with Meta and sustained growth in Europe and North America. This commercial momentum confirms the group's strategy of diversifying beyond traditional optics towards wearable technologies and connected health solutions. Additionally, the announcement the day before of the acquisition of RetinAI, a Swiss company specializing in artificial intelligence applied to the diagnosis and monitoring of eye diseases, also contributed to the positive market reception. This operation is part of a series of recent strategic moves, including the early October completion of the acquisition of Optegra, a network of over 70 ophthalmology clinics in Europe. These acquisitions reinforce the group's ambition to position itself as a major player in digital eye health, beyond its historical core business in eyewear and corrective lenses.
Technical Analysis and Future Outlook
Technically, the stock is now trading above its 50-day moving average at 268.04 euros and its 200-day moving average at 258.77 euros, indicating an established upward trend on multiple time frames. The Relative Strength Index, at 56, is in a neutral zone, with no overbought or oversold signals, leaving room for further movement. The Bollinger Bands, which frame fluctuations between 267.34 euros and 282.17 euros, show that the price is approaching the upper limit, which may suggest a consolidation phase ahead or a test of the resistance identified at 282.80 euros. Regarding momentum indicators, the MACD displays a negative histogram at -1.02, indicating that the recent upward momentum is taking a technical pause despite the day's progress. The Chaikin Money Flow, slightly negative at -0.07, indicates still timid capital flows, consistent with the low volume of trading observed. The nearest support is at 259.60 euros, providing a safety margin of about 6% from the current price, while the resistance at 282.80 euros represents a potential for progression of 2.2% before a possible slowdown.
